Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Yahoo News
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based…
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirat…
-
General20 hours agoWA Police investigate death of baby in Baldivis in Perth’s southern suburbs
-
Noosa News16 hours agoPrimary school boy dies following e-bike crash on the Sunshine Coast
-
Noosa News16 hours agoFatal e-bike crash, Mountain Creek (Sunshine Coast)
-
Business22 hours agoHow to stay calm and profit from an ASX share market crash